Department of Radiation Oncology
Neoplasms | Oncology | Respiratory Tract Diseases | Therapeutics
At the time we agreed to edit this special edition of Frontiers in early 2017, the immunotherapy revolution was already established in the second-line treatment of metastatic non-small cell lung cancer (NSCLC) and even to a select group of patients (those whose tumor cells expressed PD-L1 of ≥50%) in the first-line treatment of metastatic disease. We felt that the summarization and understanding of the strengths and benefits of our local modalities were needed prior to the possible integration of immunotherapy into the treatment paradigms of Stages I–III NSCLC and small cell lung cancer (SCLC).
lung cancer, lung cancer treatment, multi-modality treatment, radiation therapy, thoracic surgery
Rights and Permissions
Copyright: © 2018 Varlotto and Veronesi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
DOI of Published Version
Front Oncol. 2018 Jun 18;8:233. doi: 10.3389/fonc.2018.00233. eCollection 2018. Link to article on publisher's site
Frontiers in oncology
Varlotto, John M. and Veronesi, Giulia, "Editorial: Controversies in the Local Management of Lung Cancer" (2018). Open Access Articles. 3509.
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.